These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?

Institutional investors including Bank of Nova Scotia (which boosted its stake by 29%) and Vanguard have been adding Johnson & Johnson shares as the stock is up roughly 45% year-to-date; J&J posted Q3 sales of $24 billion (up 6.8% year-over-year) and adjusted EPS of $2.80 (up 15.7%). The company’s diversified portfolio — a medtech business that accounted for more than 35% of revenue, new product drivers like Carvykti (> $1bn annual sales) and a pipeline including a potential Ottava robotic-assisted surgery system — underpins resilience against patent cliffs, government drug-price negotiations and talc litigation. J&J’s top-tier credit rating and 50+ year dividend-growth track record support its capacity to manage liabilities, but ongoing legal exposure and pricing pressures leave the medium-term outlook and upside uncertain.

Analysis

Institutional investors including Bank of Nova Scotia (which increased its stake by 29%) and Vanguard have added Johnson & Johnson shares as the stock trades roughly 45% year-to-date, a backdrop the signals describe as moderately positive and supportive of continued investor interest. Recent buying by large institutions suggests conviction in the company’s near-term resiliency despite prior multi-year headwinds.

Johnson & Johnson reported third-quarter sales of $24.0 billion, up 6.8% year-over-year, and adjusted EPS of $2.80, up 15.7% year-over-year; management offset lost Stelara exclusivity with contributions from newer launches such as Carvykti (generating over $1 billion annually) and a medtech business that comprised over 35% of revenue in Q3. The diversified portfolio and pipeline have mitigated the financial impact of a single product decline and supported stronger earnings.

Material risks remain: government drug-price negotiations slated to take effect next year, ongoing talc litigation (courts have rejected a bankruptcy maneuver), patent cliffs for key drugs, and potential tariff-driven margin pressure. J&J’s highest-available credit rating and 50+ year dividend-growth record underpin balance-sheet strength and income appeal, while regulatory approval of the Ottava robotic-assisted surgery system represents a meaningful upside catalyst.

Key Decisions for Investors

• Consider adding or initiating a position on selective pullbacks given institutional accumulation, strong Q3 results, and diversified revenue drivers
• Monitor three near-term catalysts closely: implementation of government drug-price negotiations next year, major talc-litigation rulings, and regulatory progress for the Ottava RAS system
• Position for income investors may be appropriate due to J&J’s top-tier credit rating and 50+ year dividend track record, but size exposure conservatively to account for legal and pricing risks
• Use targeted hedges or limit position concentration to mitigate downside from patent cliffs, tariff risk, or adverse litigation outcomes